Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 May 26;8(4):e1021.
doi: 10.1212/NXI.0000000000001021. Print 2021 Jul.

Single-Dose Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Martijn Beudel  1 , Fleur Rövekamp  2 , Diederik van de Beek  2 , Matthijs Brouwer  2
Affiliations
Case Reports

Single-Dose Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Martijn Beudel et al. Neurol Neuroimmunol Neuroinflamm. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure. Axial MRI FLAIR and Contrast-Enhanced T1 Images (Radiologic Convention, Left = Right) of the 2 Patients at Baseline (T = 0) and after 6 months (T+6 M)
In patient 1 (upper row), at baseline, multiple hyperintense lesions on the fluid-attenuated inverse recovery (FLAIR) sequence were visible. The largest was located in the left parietal cortex. The lesions included the U fibers. After IV gadolinium, no contrast enhancement was visible. At ±6 months, the size of the lesions had decreased and atrophy was visible in the affected areas. In patient 2 (lower row), at baseline, multiple hyperintense lesions on the FLAIR sequence were visible. The largest was located in the left parietal cortex. The lesions included the U fibers. After IV gadolinium, ring enhancement was visible. At ±6 months, the lesions were less outspoken and no contrast enhancement was visible anymore.
See this image and copyright information in PMC

References

    1. Berger JR, Aksamit AJ, Clifford DB, et al. . PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology. 2013;80(15):1430-1438. - PMC - PubMed
    1. Kartau M, Verkkoniemi-Ahola A, Paetau A, et al. . The incidence and predisposing factors of John Cunningham virus-induced progressive multifocal leukoencephalopathy in Southern Finland: a population-based Study. Open Forum Infect Dis. 2019;6(2):ofz024. - PMC - PubMed
    1. Berger JR. PD-1 inhibition: a novel approach to the treatment of progressive multifocal leukoencephalopathy. Ann Transl Med. 2019;7(Suppl 8):S281. - PMC - PubMed
    1. Cortese I, Muranski P, Enose-Akahata Y, et al. . Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med. 2019;380(17):1597-1605. - PubMed
    1. Küpper C, Heinrich J, Kamm K, Bücklein V, Rothenfusser S, Straube A. Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e628. - PMC - PubMed

Publication types

LinkOut - more resources